Eating Disorders News

SAN DIEGO — Dasotraline, a dopamine and norepinephrine reuptake inhibitor, significantly decreased binge-eating days per week and was well-tolerated among adults with binge-eating disorder, according to data presented at the American Psychiatric Association Annual Meeting.

Decision-making abilities in risky scenarios, in which information about contingencies was available, were impaired among people with obesity compared with those without obesity, according to recently published findings from France.

Researchers found a positive association between anorexia nervosa and celiac disease, both before and after celiac diagnosis, in a Swedish nationwide study.

Opiant Pharmaceuticals announced the initiation of a phase 2 clinical trial assessing OPNT001, a nasally-delivered opioid antagonist, for bulimia nervosa.

Recent findings suggested that brain response to prediction error during a reward task may indicate illness severity among adolescents with anorexia nervosa.

Deep brain stimulation improved BMI, depression, anxiety and affective regulation outcomes among individuals with treatment-resistant anorexia nervosa, according to recent findings.

Susan Weiner, MS, RDN, CDE, CDN, talks with Asha Brown, founder and executive director of We Are Diabetes, Ann Goebel-Fabbri, PhD, a clinical psychologist and specialist in eating disorders in type 1 diabetes, and Erin M. Akers, executive director of the Diabulimia Helpline.

Transcranial direct current stimulation briefly improved symptoms of bulimia nervosa in adults, according to recent findings.

Recent findings indicated eating disorders were common among women in mid-life and risk factors differed among eating disorder subtypes.

Sunovion Pharmaceuticals recently announced dasotraline, a dopamine and norepinephrine reuptake inhibitor, met its primary efficacy endpoint for moderate-to-severe binge-eating disorder in adults, but did not meet its primary endpoint for ADHD in adults.